Literature DB >> 21487107

Quinine-induced thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro.

José Perdomo1, Feng Yan, Zohra Ahmadi, Xing-Mai Jiang, Roland Stocker, Beng H Chong.   

Abstract

The development of immune cytopenias is a well-recognized side effect of many drugs. Quinine- and quinidine-dependent antibodies are classic examples of drug-induced effects that cause severe, life-threatening thrombocytopenia. Whereas the effects of drug-dependent antibodies on platelets have been well documented, their effects on megakaryocyte (Mk) biology are still unclear. We analyzed sera from several quinine-induced thrombocytopenia (QITP) patients on highly pure Mks (98% glycoprotein IIb-positive [GPIIb(+)]; 92% GPIX(+)) derived from human CD34(+) cells cultured with human thrombopoietin. We demonstrate by flow cytometry and confocal microscopy that QITP IgGs bind Mks efficiently in the presence of quinine. Incubation of day-4 Mks with QITP sera or purified IgG resulted in induction of apoptosis, a significant decrease in cell viability, and an increase in cell death. Furthermore, QITP sera preferentially reduced the number of late GPIX(+)/GPIbα(+) Mks and the number of receptors per cell in the surviving population. Ploidy distribution, lobularity, and average cell size of Mks remained unchanged after treatment. In addition, treated Mks showed a marked decrease in their proplatelet production capacity, suggesting that drug-dependent antibodies hinder platelet production. Therefore, QITP antibodies considerably reduce the proplatelet production capabilities of Mks despite undetectable effects on DNA content, morphology, and cell size.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487107     DOI: 10.1182/blood-2010-10-314310

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Quinine-induced severe thrombocytopenia: the importance of taking a detailed drug history.

Authors:  Muhajir Mohamed; Robert Hayes
Journal:  BMJ Case Rep       Date:  2013-10-03

2.  Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.

Authors:  Muna Iraqi; Jose Perdomo; Feng Yan; Philip Y-I Choi; Beng H Chong
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

3.  Immune thrombocytopenia associated with consumption of tonic water.

Authors:  F David Winter
Journal:  Proc (Bayl Univ Med Cent)       Date:  2015-04

Review 4.  A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.

Authors:  D M Arnold; S Kukaswadia; I Nazi; A Esmail; L Dewar; J W Smith; T E Warkentin; J G Kelton
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

Review 5.  Approach to the diagnosis and management of drug-induced immune thrombocytopenia.

Authors:  Donald M Arnold; Ishac Nazi; Theodore E Warkentin; James W Smith; Lisa J Toltl; James N George; John G Kelton
Journal:  Transfus Med Rev       Date:  2013-07-08

6.  Taste test using an edible taste film kit: a randomised controlled trial.

Authors:  Ji-Sun Kim; Dong-Hyun Kim; Eun-Ju Jeon; Byung Guk Kim; Jeongjun Yu; Hyun-Il Shin
Journal:  BMJ Open       Date:  2019-09-27       Impact factor: 2.692

Review 7.  Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia.

Authors:  Jose Perdomo
Journal:  Immunotargets Ther       Date:  2016-02-22

8.  Pro-arrhythmogenic Effects of the V141M KCNQ1 Mutation in Short QT Syndrome and Its Potential Therapeutic Targets: Insights from Modeling.

Authors:  Hsiang-Chun Lee; Yoram Rudy; Hongwu Liang; Chih-Chieh Chen; Ching-Hsing Luo; Sheng-Hsiung Sheu; Jianmin Cui
Journal:  J Med Biol Eng       Date:  2017-07-05       Impact factor: 1.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.